Current Edition

Abzena

How to Coordinate Your Site Selection With State Economic Development

Where are your labs located? Development/pilot/clinical material facilities? Commercial plants? If these do not exist, where should you build them? If outsourcing, where are your …

Continue Reading →
CDMO

The Importance of Clinical Trial Packaging and The Benefits in Outsourcing Your Small Molecule Packaging to a CDMO

Operating a clinical trial in what is a tightly regulated industry requires comprehensive, big picture thinking. Risks remain at all stages of the clinical supply …

Continue Reading →
Aragen

Aragen expects to ride wave of US biotech growth in 2022 – influx of discovery capital is surging demand for CDMO services

Company plans wide-ranging investments and expansions to keep pace with demand driven by macro-changes and diversifying client base Aragen Life Sciences (formerly, GVK BIO), a leading …

Continue Reading →
approval

WuXi STA first CDMO to support the approval of an innovative drug in China through the “MAH” pilot

WuXi STA enables Ascletis to receive NDA Approval from China FDA for Ganovo® STA Pharmaceutical Co., Ltd. (WuXi STA), a subsidiary of WuXi AppTec, announces …

Continue Reading →
API

Ardena acquires Syntagon and strengthens API offering

Contract development and manufacturing organisation (CDMO) Ardena has acquired Syntagon, a leading contract manufacturer of novel active pharmaceutical ingredients (APIs) and excipients. The acquisition, which …

Continue Reading →
API

Saneca Pharma strengthens team with new sales director

Slovakia-based contract development and manufacturing organization (CDMO) Saneca Pharma has strengthened its team with the appointment of a new CDMO sales director as it continues …

Continue Reading →
CDMO

Recipharm equips a further three facilities for US serialisation

Recipharm, a leading contract development and manufacturing organisation (CDMO) has equipped three more of its facilities with serialisation capabilities in line with the US regulatory …

Continue Reading →
ADC

Poor aggregation will see ADC targets fail or face long delays

ADC Biotechnology (ADC Bio)‘s leading experts warn that best in class ADCs are being overlooked due to critical aggregation control problems. CDMOs are unable to …

Continue Reading →